Buchumschlag

Survival in patients with chronic thromboembolic pulmonary hypertension treated with riociguat versus other medications: a COMPERA analysis

Extract: Current treatment options for patients with chronic thromboembolic pulmonary hypertension (CTEPH) include surgical pulmonary endarterectomy (PEA), interventional balloon pulmonary angioplasty (BPA) and medical therapy [1, 2]. For many years, medical treatment primarily involved off-label us...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Held, Matthias (VerfasserIn) , Pausch, Christine (VerfasserIn) , Huscher, Doerte (VerfasserIn) , Pittrow, David (VerfasserIn) , Halank, Michael (VerfasserIn) , Beckmann, Stephan (VerfasserIn) , Stadler, Stefan (VerfasserIn) , Tello, Khodr (VerfasserIn) , Grünig, Ekkehard (VerfasserIn) , Opitz, Christian (VerfasserIn) , Delcroix, Marion (VerfasserIn) , Ghofrani, H. Ardeschir (VerfasserIn) , Behr, Juergen (VerfasserIn) , Skride, Andris (VerfasserIn) , Skowasch, Dirk (VerfasserIn) , Vonk-Noordegraaf, Anton (VerfasserIn) , Ulrich, Silvia (VerfasserIn) , Klose, Hans (VerfasserIn) , Rosenkranz, Stephan (VerfasserIn) , Olsson, Karen M. (VerfasserIn) , Hoeper, Marius M. (VerfasserIn) , Kopec, Grzegorz (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 8 December 2025
In: ERJ Open Research
Year: 2025, Jahrgang: 11, Heft: 6, Pages: 1-5
ISSN:2312-0541
DOI:10.1183/23120541.00230-2025
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1183/23120541.00230-2025
Verlag, kostenfrei, Volltext: https://publications.ersnet.org/content/erjor/11/6/00230-2025
Volltext
Verfasserangaben:Matthias Held, Christine Pausch, Doerte Huscher, David Pittrow, Michael Halank, Stephan Beckmann, Stefan Stadler, Khodr Tello, Ekkehard Grünig, Christian Opitz, Marion Delcroix, H. Ardeschir Ghofrani, Juergen Behr, Andris Skride, Dirk Skowasch, Anton Vonk-Noordegraaf, Silvia Ulrich, Hans Klose, Stephan Rosenkranz, Karen M. Olsson, Marius M. Hoeper and Grzegorz Kopec
Beschreibung
Zusammenfassung:Extract: Current treatment options for patients with chronic thromboembolic pulmonary hypertension (CTEPH) include surgical pulmonary endarterectomy (PEA), interventional balloon pulmonary angioplasty (BPA) and medical therapy [1, 2]. For many years, medical treatment primarily involved off-label use of drugs approved for pulmonary arterial hypertension, despite limited and sometimes inconclusive evidence supporting their effectiveness in CTEPH patients. In 2014, riociguat, a soluble guanylate cyclase stimulator, became the first drug approved for treating patients with inoperable CTEPH or persistent/recurrent pulmonary hypertension (PH) post-surgery [3]. Parenteral treprostinil was subsequently approved for CTEPH [4], although its use has remained limited, likely due to the invasiveness and associated side-effects.
Beschreibung:Online veröffentlicht: 8. Dezember 2025
Gesehen am 20.02.2026
Beschreibung:Online Resource
ISSN:2312-0541
DOI:10.1183/23120541.00230-2025

Ähnliche Einträge